A novel tau-SH3 blocking peptide was tested in an in vitro Alzheimer’s disease model and has been shown to ameliorate amyloid-beta toxicity in neurons without affecting the activity of Fyn kinase [49]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.